US 11,896,713 B2
Strategies to enhance lung cancer treatment
Tamara Minko, East Brunswick, NJ (US); and Olga B. Garbuzenko, Skillman, NJ (US)
Assigned to Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Oct. 22, 2021, as Appl. No. 17/508,535.
Claims priority of provisional application 63/104,131, filed on Oct. 22, 2020.
Prior Publication US 2022/0125728 A1, Apr. 28, 2022
Int. Cl. A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 31/282 (2006.01); A61K 33/243 (2019.01); A61K 31/704 (2006.01); A61P 35/00 (2006.01); A61K 31/5377 (2006.01); A61K 31/506 (2006.01); A61K 31/553 (2006.01); A61K 31/365 (2006.01); A61K 31/277 (2006.01); A61K 47/64 (2017.01); A61K 31/517 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 9/0078 (2013.01); A61K 31/277 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/365 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 47/64 (2017.08); A61P 35/00 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A nanocarrier system formulated for in vivo delivery of an anticancer agent by inhalation, comprising:
(a) a lipid nanoparticle comprising a lipid matrix consisting essentially of at least one lipid that is solid at room temperature and at least one lipid that is liquid at room temperature;
(b) an anticancer agent incorporated in imperfections in the lipid matrix;
(c) a first group of polyethylene glycols (PEGs) extending from the surface of the nanoparticle, wherein the PEGs each have an inner terminus bonded to an anchor lipid in the nanoparticle and an outer terminus;
(d) a ligand bonded to the outer terminus of the first group of PEGs, wherein the ligand is specific to receptors overexpressed in cancer cells; and
(e) one or more siRNAs distributed on the surface of the nanoparticle;
wherein the lipid nanoparticle is not a liposome.